Shots:

• The companies discontinue the P-IIa study assessing BI 1467335 vs PBO in 79 patients with moderately severe to severe NPDR without CIDME for 12wks. treatment period with an additional 12wks. follow-up period afterward. The study met its 1EPs in ocular safety with the treatment being well-tolerated
• The discontinuation is due to a lack of a clear efficacy signal and risk of dose-dependent drug interactions of the compound in NPDR patients identified in another P-I study. Additionally- Boehringer Ingelheim has terminated its 2015 agreement with Pharmaxis with 90 days notice period
• Boehringer Ingelheim will deploy its expertise in multiple therapeutic areas and will advance  its portfolio of next-generation retinal therapy approaches while Pharmaxis will continue its development of amine oxidase inhibitors with a P-II study in myelofibrosis- commencing later this year

­ Ref: Boehringer Ingelheim | Image: Barnet Dulaney Perkins Eye Center